Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, combination, duration of use, route of administration, and timing of initiation. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of